Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
暂无分享,去创建一个
Jiong Cai | Zhijun Wu | J. Qin | Wei Xu | Wei Tian | J. Zheng | W. Dong | Tao Wu | Hongming Wang | Yan Zhang | Ze-min Xiao | Yang-feng Du | Shiyan Li
[1] M. Ang,et al. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions. , 2022, Current treatment options in oncology.
[2] Wenliang Liu,et al. Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations , 2022, Frontiers in Pharmacology.
[3] Cuidan Li,et al. Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy. , 2022, Clinical lung cancer.
[4] K. Zeng,et al. Perioperative targeted therapy for oncogene-driven NSCLC. , 2022, Lung cancer.
[5] N. Girard,et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.
[6] Y. Yang,et al. 81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results , 2022, Annals of Oncology.
[7] Fanshuang Zhang,et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC , 2021, Nature Communications.
[8] P. Jänne,et al. Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study , 2021, ESMO open.
[9] M. Tsuboi,et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA , 2021, Future oncology.
[10] M. Tsuboi,et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. , 2021, Journal of Thoracic Oncology.
[11] M. Okada,et al. A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study) , 2021, Therapeutic Advances in Medical Oncology.
[12] Changlian Lu,et al. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma , 2020, Journal of Cancer Research and Clinical Oncology.
[13] Ying Cheng,et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Tajima,et al. Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations. , 2018, Lung cancer.
[15] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[16] Ash A. Alizadeh,et al. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.
[17] Sarah Burdett,et al. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.
[18] Y. Ichinose,et al. The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene. , 2013, Lung cancer.
[19] N. Sakakura,et al. Pulmonary carcinosarcoma successfully resected using the rib-cross thoracotomy approach: report of a case , 2012, Surgery Today.
[20] Yih-Leong Chang,et al. EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy , 2011, Annals of Surgical Oncology.
[21] Richard J Stephens,et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] G. Strauss. Management of early-stage lung cancer: past, present, and future adjuvant trials. , 2006, Oncology.
[23] J. C. Belisario,et al. Report on a case of? , 1954, Australian journal of dermatology.